One of the challenges of HIV research has been that no good mouse models exist for the disease, meaning that a lot of animal work needs to be done in primates. Read More
• Cubist Pharmaceuticals Inc., of Lexington, Mass., reported second-quarter revenues of $230.6 million, and earnings per share of 58 cents, solidly beating analyst estimates of 45 cents per share. The company reported net revenues of $212 million for antibiotic Cubicin (daptomycin), an increase of 20 percent over the second quarter of 2011. Read More
• Bristol-Myers Squibb Co., of New York, said its candidate for liver cancer, brivanib, did not meet its primary overall survival objective based on a noninferiority statistical design in the Phase III BRISK-FL trial. Read More
• Shire plc, of Dublin, Ireland, reported that its wholly owned subsidiary Advanced BioHealing Inc., which was acquired in 2011, has changed its name to Shire Regenerative Medicine Inc. The change follows Shire's announcement that it planned to build a regenerative medicine campus in San Diego to expand its operational footprint and presence in the area over the next several years. Read More
• Celgene International Sarl, of Boudry, Switzerland, a subsidiary of Celgene Corp., said it will request a re-examination of the negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) regarding Istodax (romidepsin) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Read More
After getting hammered a month ago on news of a missed primary endpoint in the Phase IIb PEARL-SC study of lupus drug blisibimod, shares of Anthera Pharmaceuticals Inc. rebounded last week when the Hayward, Calif.-based firm released promising data from a subset of patients in the study. Read More
Sanofi SA and Regeneron Pharmaceuticals Inc. began enrolling patients for several trials within its Phase III program for REGN727, an antibody for lowering LDL cholesterol. Read More
WASHINGTON – It was an encore performance in the Federal Circuit Friday as the panel of judges that ruled on the Association for Molecular Pathology v. Myriad Genetics Inc. last year listened to pretty much the same arguments about the patentability of isolated DNA all over again. Read More
LONDON – The first gene therapy to be approved in a Western regulated market finally made it over the finishing line on Thursday when the European Medicines Agency (EMA) gave the nod to Glybera after considering the treatment for lipoprotein lipase deficiency (LPL) for the fourth time. Read More
Shares of Onyx Pharmaceuticals Inc. jumped 11.7 percent Friday after its multiple myeloma drug Kyprolis (carfilzomib) won accelerated approval as a third-line treatment. Read More
